These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29572578)

  • 1. Crucial role of P2X
    Takeda A; Yamada H; Hasegawa E; Arima M; Notomi S; Myojin S; Yoshimura T; Hisatomi T; Enaida H; Yanai R; Kimura K; Ishibashi T; Sonoda KH
    Jpn J Ophthalmol; 2018 May; 62(3):398-406. PubMed ID: 29572578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
    Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
    Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
    Keino H; Watanabe T; Sato Y; Okada AA
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1548-56. PubMed ID: 20861477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
    Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
    Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant natural killer T cells play dual roles in the development of experimental autoimmune uveoretinitis.
    Satoh M; Namba KI; Kitaichi N; Endo N; Kitamei H; Iwata D; Ohno S; Ishida S; Onoé K; Watarai H; Taniguchi M; Ishibashi T; Stein-Streilein J; Sonoda KH; Van Kaer L; Iwabuchi K
    Exp Eye Res; 2016 Dec; 153():79-89. PubMed ID: 27720708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.
    Keino H; Takeuchi M; Usui Y; Hattori T; Yamakawa N; Kezuka T; Sakai JI; Usui M
    Br J Ophthalmol; 2007 Jan; 91(1):105-10. PubMed ID: 16943228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor.
    Zhang L; Ma J; Takeuchi M; Usui Y; Hattori T; Okunuki Y; Yamakawa N; Kezuka T; Kuroda M; Goto H
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2109-17. PubMed ID: 20007828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
    Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
    J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
    Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-nitrosoglutathione prevents interphotoreceptor retinoid-binding protein (IRBP(161-180))-induced experimental autoimmune uveitis.
    Haq E; Rohrer B; Nath N; Crosson CE; Singh I
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):221-31. PubMed ID: 17593005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
    Keino H; Watanabe T; Sato Y; Niikura M; Wada Y; Okada AA
    Arthritis Res Ther; 2008; 10(5):R122. PubMed ID: 18847496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGB1 release triggered by the interaction of live retinal cells and uveitogenic T cells is Fas/FasL activation-dependent.
    Jiang G; Wang Y; Yun J; Hajrasouliha AR; Zhao Y; Sun D; Kaplan HJ; Shao H
    J Neuroinflammation; 2015 Sep; 12():179. PubMed ID: 26394985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
    Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
    J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of exogenous interleukin-2, interleukin-23 on differentiation of IRBP 1-20-specific T cells toward Th1 and Th17 and comparison of the pathogenicity of IRBP 1-20-specific T cells].
    Li Y; Cui Y; Bi HS; Wang Y; Li J; Wang XR
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):224-9. PubMed ID: 23866703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
    Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
    Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis.
    Yang H; Zheng S; Mao Y; Chen Z; Zheng C; Li H; Sumners C; Li Q; Yang P; Lei B
    Clin Exp Immunol; 2016 Feb; 183(2):280-93. PubMed ID: 26400205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).
    Vistica BP; Shi G; Nugent L; Tan C; Altman A; Gery I
    Mol Vis; 2012; 18():1858-64. PubMed ID: 22815639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.